Precigen, Inc.
(NASDAQ : XON)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.23%430.810.0%$5896.50m
BNTXBioNTech SE -4.25%356.820.0%$1229.39m
NVAXNovavax, Inc. -0.97%234.9779.4%$930.24m
SNSSSunesis Pharmaceuticals, Inc. 1.29%8.630.7%$603.27m
AMGNAmgen, Inc. -0.09%217.171.4%$527.46m
REGNRegeneron Pharmaceuticals, Inc. -1.21%645.262.7%$516.44m
GILDGilead Sciences, Inc. -0.77%70.781.0%$418.38m
ILMNIllumina, Inc. -0.90%445.893.5%$376.71m
TECHBio-Techne Corp. 0.17%530.344.5%$328.86m
BIIBBiogen, Inc. -0.90%297.001.7%$290.16m
VRTXVertex Pharmaceuticals, Inc. -0.17%186.781.9%$230.17m
ISEEIVERIC bio, Inc. -2.23%16.000.0%$184.96m
BGNEBeiGene Ltd. 6.40%409.911.3%$169.60m
LIFEaTyr Pharma, Inc. -7.68%9.473.2%$128.59m
KDMNKadmon Holdings, Inc. -0.62%8.770.9%$127.36m

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Trans Ova segment includes provides advanced reproductive technologies. The Human Biotherapeutics segment accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.